Phase Ib/II Neoadjuvant Trial of the Farnesyltransferase Inhibitor, R115777 With Docetaxel and Capecitabine for Patients With Stage IIIA or IIIB Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 07 May 2015
At a glance
- Drugs Tipifarnib (Primary) ; Capecitabine; Docetaxel
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 28 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 28 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Sep 2005 New trial record.